Navigation Links
PETA International Science Consortium disappointed in denial of Dow appeal
Date:6/19/2013

The PETA International Science Consortium (PISC) is extremely disappointed that the European Chemicals Agency (ECHA) Board of Appeal has upheld a decision that requires Dow Benelux B.V.to conduct a pre-natal developmental toxicity study in rats. The study will use approximately 1160 animals and expose pregnant rats and their unborn pups to the substance dipropylene glycol methyl ether acetate (DPMA) in order to comply with the European Community's Regulation on the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH).

PISC urges the Board of Appeal to demonstrate greater independence when making decisions regarding the justification of read-across arguments in future appeal cases.

The substance DPMA hydrolyses to dipropylene glycol methyl ether (DPM), for which data are already available. In an appeal filed on January 24, 2012, the company rightfully argued that the testing requirement was, therefore, satisfied using read-across arguments.

The Board of Appeal's decision means that pregnant rats will be forced to consume high concentrations of the chemical over a 16 day period before being killed and their offspring, dissected. Read-across arguments are a mechanism by which large numbers of animal tests can be avoided which makes this decision even more disappointing as it may unjustifiably discourage other chemical manufacturers from using valid read-across arguments which could ultimately lead to hundreds of thousands of additional animals being used. As many as ten million animals could be used in testing conducted for REACH.

The European Ombudsman is currently considering a complaint submitted by PETA in July 2012 alleging that ECHA is failing to ensure that animal testing is conducted only as a "last resort," as required by the REACH regulation.


'/>"/>

Contact: Gilly Stoddart
GillyS@peta.org.uk
44-207-837-6327
People for the Ethical Treatment of Animals
Source:Eurekalert

Page: 1

Related biology news :

1. First international collaboration to showcase latest body of evidence of dairy health benefits
2. SPIE on global team proposing International Year of Light at United Nations
3. CLEO: 2013 -- the Premier International Laser and Electro-Optics Event in San Jose next week
4. New review sets international standards for best practice in fracture liaison services
5. BGI hosts its 2nd International Conference on Genomics in the Americas
6. Drive-Up Biometric System from SRI International Sarnoff Wins New Product Showcase Award at ISC West 2013
7. International conference will put agri-food supply chain under the microscope
8. International collaboration to investigate disappearing reptiles and amphibians
9. International conference to tackle climate-change threats to agriculture
10. International study: Excess dietary salt may drive the development of autoimmune diseases
11. International consortium builds Google Map of human metabolism
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... 2014) Scientists at The New York Stem ... closer to creating a viable cell replacement therapy ... , For the first time, NYSCF scientists ... skin samples of patients with primary progressive multiple ... to induce these stem cells into becoming oligodendrocytes, ...
(Date:7/24/2014)... York, NY - July 24, 2014 -- Keryx Biopharmaceuticals, ... from the long-term, randomized, active control Phase 3 study ... iron-based phosphate binder, for the treatment of hyperphosphatemia in ... PERFECTED study (PhosphatE binding and iRon delivery with FErric ... Journal of the American Society of Nephrology ...
(Date:7/24/2014)... YORK, NY (July 24, 2014) Scientists at ... Institute are one step closer to creating a ... a patient,s own cells. , For the ... (iPS) cells lines from skin samples of patients ... developed an accelerated protocol to induce these stem ...
Breaking Biology News(10 mins):NYSCF scientists one step closer to cell therapy for multiple sclerosis patients 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4NYSCF scientists 1 step closer to cell therapy for multiple sclerosis patients 2
... Hopkins scientists seems to have discovered an almost-too-easy way to ... potent versions. Their finding, reported this week in Nature, could ... but also other body tissues. What the researchers ... neural stem cells the sort that might be used ...
... The giant panda is not at an evolutionary dead end ... new research involving scientists from Cardiff University. Previous ... requirements and slow reproductive rates have led to a lack ... extinction. Now a study by Professor Michael Bruford ...
... August 23, 2007 On August 16, the Food and ... sold under the brand name Coumadin. The new label suggests ... be safer for patients with variations in two genes, CYP2C9 ... testing, which may be a useful tool in determining appropriate ...
Cached Biology News:When is a stem cell not really a stem cell? 2American College of Medical Genetics responds to new FDA labeling decision for warfarin 2
(Date:7/24/2014)... DUBLIN , July 24, 2014 ... the "Global Cell Culture Market 2014-2018" report ... Cell culture is the in vitro ... such as research, cell studies, and biopharmaceutical production. Cell ... vaccine production. Cell culture instruments and cell culture consumables ...
(Date:7/24/2014)... Your cell phone may stay charged ... storage capacity. , New research indicates that lithium-ion ... at Lawrence Livermore National Laboratory and ... components will perform as electrodes. , The growing ... for higher-performance batteries. Several key characteristics of lithium-ion ...
(Date:7/24/2014)...  CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical ... for the prevention and treatment of cardiorenal and ... July 18, 2014 from the NYSE MKT LLC ... plan to regain compliance with continued listing standards ... is continuing the Company,s listing and has granted ...
(Date:7/24/2014)... 2014 2014 Deep Research Report ... a professional and in-depth research report on Potassium ... basic information, including its definition, classification, application, ... research covers the international market analysis, including China’s ... covering macroeconomic environment & economic situation analysis, the ...
Breaking Biology Technology:Global Cell Culture Market 2014-2018: Key Vendors are Becton, Dickinson and Co, EMD, GE Healthcare, Lonza Group, Sigma Aldrich and Thermo Fisher Scientific 2Getting More Life out of Lithium-ion Batteries 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 3Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 2Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 3Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 4
... , , ROCKVILLE, Md., ... has announced that 263 regulatory professionals achieved Regulatory Affairs ... RAC credential is administered by RAPS and is the ... product sector. , , (Logo: ...
... BEIJING, Sept. 4 /PRNewswire-Asia/ -- ... provider of biopharmaceutical products in China, announced today that,the ... Republic,of China has issued the initial order to Sinovac ... to the initial order, Sinovac is,required to complete the ...
... September 4 Karolinska Development (publ),today announced that one ... clinical study of its candidate drug, tafoxiparin, a,new drug ... promising results of the Phase II trial bring the ... strategy. , Dilafor,s candidate drug, ...
Cached Biology Technology:263 Regulatory Professionals Achieve RAC Certification 2263 Regulatory Professionals Achieve RAC Certification 3Sinovac Obtains Initial Order of H1N1 Vaccine from Chinese Central Government 2Sinovac Obtains Initial Order of H1N1 Vaccine from Chinese Central Government 3Karolinska Development Portfolio Company Completes Successful Phase II Clinical Trial 2Karolinska Development Portfolio Company Completes Successful Phase II Clinical Trial 3
Request Info...
supplied with 10x reaction buffer...
... from yeast/leuconostoc overproducer ATP: ... EC 2.7.1.1/1.1.1.49. One unit of ... of D-glucose in 1 min ... One unit of G6P-DH will ...
Request Info...
Biology Products: